IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the thirteen brokerages that are currently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $47.55.

IDYA has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their target price on IDEAYA Biosciences from $63.00 to $66.00 and gave the stock an "overweight" rating in a research report on Thursday, May 22nd. Royal Bank Of Canada upgraded shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and decreased their price objective for the company from $57.00 to $30.00 in a report on Wednesday. The Goldman Sachs Group upgraded shares of IDEAYA Biosciences to a "hold" rating and set a $25.00 target price on the stock in a research note on Thursday. Finally, Wells Fargo & Company assumed coverage on shares of IDEAYA Biosciences in a research note on Thursday, June 26th. They set an "overweight" rating and a $44.00 price target for the company.

Institutional Trading of IDEAYA Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in IDYA. GF Fund Management CO. LTD. purchased a new stake in IDEAYA Biosciences in the fourth quarter valued at about $47,000. CWM LLC increased its holdings in shares of IDEAYA Biosciences by 325.7% during the first quarter. CWM LLC now owns 2,371 shares of the company's stock valued at $39,000 after acquiring an additional 1,814 shares in the last quarter. PNC Financial Services Group Inc. raised its position in shares of IDEAYA Biosciences by 180.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company's stock valued at $39,000 after purchasing an additional 1,546 shares during the last quarter. Daiwa Securities Group Inc. boosted its stake in IDEAYA Biosciences by 44.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock worth $72,000 after purchasing an additional 853 shares in the last quarter. Finally, Signaturefd LLC grew its position in IDEAYA Biosciences by 374.8% during the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company's stock worth $47,000 after purchasing an additional 2,271 shares during the last quarter. Hedge funds and other institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Stock Down 1.4%

Shares of NASDAQ:IDYA traded down $0.32 during trading on Friday, reaching $22.48. The company's stock had a trading volume of 804,315 shares, compared to its average volume of 925,368. IDEAYA Biosciences has a 12 month low of $13.45 and a 12 month high of $44.42. The firm's 50 day simple moving average is $20.51 and its two-hundred day simple moving average is $20.53.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period in the prior year, the firm earned ($0.53) EPS. As a group, equities research analysts predict that IDEAYA Biosciences will post -3.07 earnings per share for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.